Favezelimab treatment increases the production of cytokines, such as IFN-γ, IL-2, IL-8, and TNF-α, and chemokines (CCL4, CXCL10, and CCL22) in Jurkat Clone G10-PD-1 cells (a group of cell lines obtained by coculturing Jurkat and Raji B cell lymphoma lines that express high levels of LAG-3 and PD-1). This evidence concerns the gene PDCD1 and B-cell non-Hodgkin lymphoma.